Company

Hikma

Hikma has 37 drugs tracked on RxWires: 1 post-market, 25 approved, 1 in Phase 3, 2 in Phase 2, 7 in Phase 1.

Pipeline

Drug	Phase	Indication
Pemetrexed	Post-Market	Carcinoma, Non-Small-Cell Lung
CAPTOPRIL	Approved
NEOSTIGMINE METHYLSULFATE	Approved
THIOTEPA	Approved
ROXICET	Approved
ZALEPLON	Approved
SUGAMMADEX	Approved
DICYCLOMINE HYDROCHLORIDE	Approved
RIFAMPIN AND ISONIAZID	Approved
FLUPHENAZINE DECANOATE	Approved
BUPRENORPHINE	Approved
MEFLOQUINE HYDROCHLORIDE	Approved
LIDOCAINE HYDROCHLORIDE	Approved
SUMATRIPTAN SUCCINATE	Approved
LITHIUM CARBONATE	Approved
MONTELUKAST SODIUM	Approved
CORTISONE ACETATE	Approved
FLUTICASONE PROPIONATE AND SALMETEROL	Approved
EPHEDRINE SULFATE	Approved
RIFAMPIN	Approved
AMPICILLIN SODIUM	Approved
DILTIAZEM HYDROCHLORIDE	Approved
TAPENTADOL HYDROCHLORIDE	Approved
AZELASTINE HYDROCHLORIDE	Approved
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE	Approved
ACETAZOLAMIDE	Approved
praziquantel	Phase 3	Schistosomiasis
Dasatinib	Phase 2	Chronic Myelogenous Leukemia
Epinephrine Nasal Spray, 2.5 mg	Phase 2	Epinephrine
Topoprazan	Phase 1	Healthy
Ekmasonid	Phase 1	Healthy
Sphingomod	Phase 1	Healthy
Doxirazole	Phase 1	Healthy
Azacitidine	Phase 1	Acute Myeloid Leukaemia
Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose)	Phase 1	Healthy
Empagliflozin & Metformin (Test)	Phase 1	Healthy
Ferric carboxymaltose (FCM)	Not Applicable	Anemia

Follow Hikma on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.

Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.